Can polycystic ovary syndrome (PCOS) cause fetal growth restriction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

PCOS and Fetal Growth Restriction

Yes, PCOS can cause fetal growth restriction (FGR), though the evidence shows a modest but real association that appears to be independent of maternal BMI. The most recent high-quality evidence demonstrates that offspring of mothers with PCOS have significantly lower birth weights, shorter birth lengths, and smaller head circumferences compared to controls 1, 2.

Evidence for the Association

The 2024 cohort study by Hanem et al., which combined data from three clinical trials and the Norwegian Mother and Child Cohort Study (n=390 PCOS pregnancies vs 68,708 controls), provides the strongest recent evidence 1. This study found:

  • Birth weight z-score reduction of -0.26 (95% CI, -0.38 to -0.14)
  • Birth length z-score reduction of -0.19 (95% CI, -0.33 to -0.05)
  • Head circumference z-score reduction of -0.13 (95% CI, -0.26 to -0.01)
  • Lower placenta weight (-24g; 95% CI, -43 to -5g)
  • Higher birth weight to placenta weight ratio (0.4; 95% CI, 0.3 to 0.5)

Critically, this growth restriction was MORE pronounced when adjusting for BMI, suggesting PCOS itself—not just obesity—contributes to FGR 1.

Supporting Evidence from Meta-Analyses

A 2024 systematic review and meta-analysis of 73 studies (92,881 offspring) confirmed that mothers with PCOS have 2:

  • Higher odds of FGR
  • Higher odds of low birth weight
  • Lower mean birthweight overall
  • These associations persist even after adjusting for BMI

An earlier 2005 study found the prevalence of small-for-gestational-age (SGA) infants was significantly higher in PCOS mothers (12.8% vs 2.8%, P<0.02) 3. Moreover, SGA infants born to PCOS mothers were smaller than SGA infants born to control mothers.

Guideline Recognition

The 2013 Endocrine Society Clinical Practice Guideline acknowledges that intrauterine growth restriction has been associated with subsequent development of PCOS in some populations, suggesting a bidirectional relationship 4. The guideline notes there is evidence that cardiovascular disease in humans is related to intrauterine events, and that intrauterine growth restriction has been associated with increased rates of coronary heart disease, hypertension, and type 2 diabetes 4.

The 2023 International Evidence-based Guideline for PCOS now emphasizes that PCOS is a "high risk status for adverse outcomes during pregnancy" and recommends that PCOS status should be captured at pregnancy to identify risk and improve birth outcomes 5.

Clinical Implications

Key Points for Practice:

  • PCOS independently increases risk of FGR, separate from obesity effects
  • The mechanism appears related to placental dysfunction rather than just metabolic factors
  • Increased neonatal morbidity is present even with small absolute differences in gestational age 4
  • Women with PCOS require preconceptual assessment of BMI, blood pressure, and oral glucose tolerance 4

Important Caveats:

The 2016 meta-analysis found that while PCOS increases risk of many pregnancy complications, the effect on FGR specifically showed heterogeneity across studies 6. However, the more recent 2024 evidence with larger sample sizes and better methodology confirms the association 1, 2.

Neither PCOS phenotype nor gestational diabetes diagnosis modified the association between PCOS and neonatal anthropometry 1, suggesting the growth restriction effect is intrinsic to PCOS itself rather than secondary to specific metabolic complications.

The evidence indicates this is not just about obesity—the growth restriction associated with PCOS appears to involve underlying placental dysfunction and possibly androgen exposure effects on fetal programming 4.

Related Questions

Can an ovarian cyst cause facial hair growth (hirsutism) in the absence of polycystic ovary syndrome?
What is the recommended dosage regimen of Celine for adult women with polycystic ovary syndrome, including starting dose, titration, maximum dose, and precautions?
In a premenopausal woman with polycystic ovary syndrome and amenorrhea who has a 5 mm endometrial stripe on transvaginal ultrasound, does she need endometrial sampling?
What are the recommended next steps to evaluate and manage a 32-year-old woman with elevated insulin levels and no prior diagnosis of polycystic ovary syndrome?
A 28-year-old woman with a two-year history of irregular menses, polycystic-appearing ovaries on ultrasound, and elevated serum testosterone—does she meet criteria for polycystic ovary syndrome (PCOS) and what management recommendations should be pursued?
Should domperidone and ciprofloxacin be avoided when taken together due to the risk of QT interval prolongation?
Do mosapride and itopride prolong the QT interval?
Why does nifedipine cause severe tachycardia (heart rate up to 170 bpm)?
In an elderly patient with an uncomplicated urinary tract infection, is cefdinir an appropriate treatment compared to first‑line agents such as nitrofurantoin, trimethoprim‑sulfamethoxazole, or fosfomycin?
What is the most likely cause of a 30‑second unresponsive episode with post‑ictal drowsiness, amnesia, bilateral upper‑limb stiffness, eyes open, no vocalization or cyanosis, in an 80‑year‑old woman with depression, coronary artery disease, hypertension, dyslipidemia, normal thyroid function tests, electrolytes, cardiac enzymes, sinus rhythm ECG and normal brain MRI?
What are the indications for prochlorperazine 5 mg?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.